Three Years Sustained Complete Remission Achieved in a Primary Refractory ALK-Positive Anaplastic T Large Cell...

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Anaplastic lymphoma kinase-positive (ALK+) anaplastic T large cell lymphoma (ALCL) has a poor prognosis, especially when refractory to initial treatments.
• Identifying molecular targets is crucial for developing targeted cancer therapies.
• Crizotinib, an ALK inhibitor, is approved for ALK-rearranged lung cancer but its use in ALK+ ALCL is limited.

Observation:

• This report details a case of primary refractory ALK+ ALCL.
• The patient received crizotinib as a single-agent therapy.
• Previous reports indicated crizotinib use primarily as a bridge to allotransplantation, not for prolonged monotherapy survival.

Findings:

• The patient achieved and sustained a complete response.
• This response lasted for over 3 years of continuous crizotinib monotherapy.
• This represents a prolonged survival outcome under crizotinib monotherapy in a challenging ALCL subtype.

Implications:

• Crizotinib monotherapy may offer a durable treatment option for select patients with primary refractory ALK+ ALCL.
• This finding could alter treatment strategies for ALK+ ALCL, potentially avoiding or delaying more intensive therapies.
• Further research into crizotinib's long-term efficacy in ALK+ ALCL is warranted.